NF-κB in Cancer Immunity: Friend or Foe? - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue (Article De Synthèse) Cells Année : 2021

NF-κB in Cancer Immunity: Friend or Foe?

Résumé

The emergence of immunotherapies has definitely proven the tight relationship between malignant and immune cells, its impact on cancer outcome and its therapeutic potential. In this context, it is undoubtedly critical to decipher the transcriptional regulation of these complex interactions. Following early observations demonstrating the roles of NF-κB in cancer initiation and progression, a series of studies converge to establish NF-κB as a master regulator of immune responses to cancer. Importantly, NF-κB is a family of transcriptional activators and repressors that can act at different stages of cancer immunity. In this review, we provide an overview of the selective cell-intrinsic contributions of NF-κB to the distinct cell types that compose the tumor immune environment. We also propose a new view of NF-κB targeting drugs as a new class of immunotherapies for cancer.
Fichier principal
Vignette du fichier
cells-10-00355.pdf (1.22 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03846765 , version 1 (18-08-2023)

Identifiants

Citer

Guilhem Lalle, Julie Twardowski, Yenkel Grinberg-Bleyer. NF-κB in Cancer Immunity: Friend or Foe?. Cells, 2021, 10 (2), pp.355. ⟨10.3390/cells10020355⟩. ⟨hal-03846765⟩
30 Consultations
12 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More